Marc Hedrick, M.D., President and CEO of Plus Therapeutics (Nasdaq: PSTV), recently sat down with Jonathan D. Grinstein, PhD, of Inside Precision Medicine to discuss the company’s exciting news: a National Coverage Agreement with UnitedHealthcare Insurance Company (NYSE: UNH) for the CNSide® Cerebrospinal Fluid (CSF) Assay.

This milestone expands access to the CNSide® CSF Tumor Cell Enumeration laboratory-developed test (LDT) — a breakthrough platform for the diagnosis and monitoring of leptomeningeal metastases (LM) and other central nervous system (CNS) cancers — to more than 51 million UnitedHealthcare members nationwide.

“Securing national payer coverage for CNSide® is a transformational moment for patients and physicians managing leptomeningeal metastases,” said Marc Hedrick, M.D. “With broader access to our precision diagnostics platform, clinicians can detect and monitor disease more accurately, ultimately improving patient care and outcomes.”

Why This Coverage Expansion Matters

• Greater Patient Access: Millions of individuals with UnitedHealthcare plans now have coverage for CNSide® testing, helping reduce financial barriers.
• Accelerated Adoption: Broader payer support drives integration of precision diagnostics into routine clinical workflows.
• Improved Outcomes: Accurate and sensitive CSF tumor cell detection allows for better-informed treatment decisions in patients with LM and other CNS cancers.

About CNSide®

CNSide® is a proprietary, highly sensitive CSF Assay Platform designed to support:

• Early detection of tumor cells in cerebrospinal fluid
• Real-time monitoring of disease progression and treatment response
• Precision-guided therapy decisions for patients with leptomeningeal metastases and other challenging CNS cancers

Performed exclusively in a CLIA-accredited laboratory, CNSide® sets a new standard for neuro-oncology diagnostics, enabling physicians to manage complex CNS cancers with greater confidence and accuracy.

Learn More

Read the full Inside Precision Medicine interview: Click Here
About CNSide® Diagnostics: CNSide Official Website
Investor Relations: Plus Therapeutics (Nasdaq: PSTV)

#PlusTherapeutics #CNSide #PSTV #LeptomeningealMetastases #LeptomeningealCancer #PrecisionDiagnostics #NeuroOncology #HealthcareInnovation #UnitedHealthcare #CNSideDiagnostics